KRAS and lung adenocarcinoma: Using a population-based study in a nationwide cohort with real-world data, we aim to describe overall survival (OS) and to evaluate the prognostic implication of KRAS G12C for treatment with first-line monoimmunotherapy and combination immuno-chemotherapy in patients with lung adenocarcinoma compared with those with a KRAS non-G12C mutation.